Management has not yet determined what indication will be pursued in the proof-of-concept study. However, etifoxine is prescribed (off-label) in Europe and other countries for depression. Furthermore, recent clinical studies have shown that increased neurosteroids have therapeutic effect for various depression indications, including Major Depressive Disorder and Post-Partum Depression. Accordingly, both indications are being evaluated as potential candidates for this study.